Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFICACY AND SAFETY OF METOPROLOL SUCCINATE IN HIGH DOSES IN PATIENTS WITH STABLE COURSE OF ISCHEMIC HEART DISEASE

https://doi.org/10.20996/1819-6446-2008-4-5-46-52

Full Text:

Abstract

Aim. To compare two initial doses (50 or 100mg/day) ofmetoprolol succinate in control released presentation (Betaloc ZOK, AstraZeneca) for achievement of target level of heart rate (HR) in patients with stable course of ischemic heart disease (IHD).

Material and methods. 50 patients (34 men and 16 women, aged 61,3 y.o., in average) with IHD were involved into the open randomized comparative study. IHD duration was from 1 to 22 years (8,3 years in average). 47 patients completed study, 3 patients drop out because of side effects. Previous therapy with β-blockers or other HR reducing drugs was replaced on metoprolol. Patients were randomized in 2 groups (G1 and G2). The initial metoprolol dose was 50 mg in G1 patients and 100 mg - in G2 patients. The dose was enlarged twice if necessary. Study duration was 6 weeks. The change of HR, blood pressure, electrocardiogram parameters was evaluated. Patients filled in Seattle angina questionnaire initially and after 6 weeks treatment. Therapy tolerability was also estimated.

Results. In 6 weeks of therapy 61% of G1 patients and 87,5% of G2 patients (p<0,01) reached HR target. Dependence of achievement of target HR and dose of metoprolol was observed (r=0,3; p=0,056). Improvement of the HR control was accompanied by reduction of frequency of angina attacks and increase of life quality.

Conclusion. Metoprolol (Betaloc ZOK) 200 mg/day provides more effective HR control in patients with IHD vs metoprolol 50-100 mg/day and has good tolerability.

About the Authors

S. N. Tolpygina
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


S. Y. Martsevich
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


References

1. Fox K., Garcia M.A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27(11):1341-81.

2. Freemantle N., Cleland J., Young P. et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.

3. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247(12):1707-14.

4. Yusuf S., Peto R., Lewis J. et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27(5):335-71.

5. Gibbons R.J., Chatterjee K., Daley J. et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33(7):2092-197.

6. Viskin S., Kitzis I., Lev E. et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25(6):1327-32.

7. Herlitz J., Dellborg M., Karlson B.W. et al. Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge. Cardiovasc Drugs Ther 2000;14(6):589-95.


For citation:


Tolpygina S.N., Martsevich S.Y. EFFICACY AND SAFETY OF METOPROLOL SUCCINATE IN HIGH DOSES IN PATIENTS WITH STABLE COURSE OF ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2008;4(5):46-52. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-5-46-52

Views: 439


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)